Drug search by name

Olumiant and Hepatic impairment

Result of checking the interaction of drug Olumiant and disease Hepatic impairment for safety when used together.

Check result:

Olumiant <> Hepatic impairment

Relevance: 23.07.2019 Reviewer: Shkutko P.M., M.D., in

When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.

Consumer:

Baricitinib is not recommended in patients with severe hepatic impairment. No dose adjustment is necessary in patients with mild or moderate hepatic impairment. Treatment with baricitinib is associated with increased incidence of liver enzyme elevation. It is recommended to evaluate liver enzymes at baseline and thereafter according to routine patient management. Prompt investigation of the cause of liver enzyme elevation is recommended to identify potential cases of drug-induced liver injury. If increases in ALT or AST are observed and drug-induced liver injury is suspected, interrupt treatment until this diagnosis is excluded.

Olumiant

Generic Name: baricitinib

Brand Name: Olumiant

Synonyms: n.a.

What is Olumiant?